NEW YORK (GenomeWeb News) — Rosetta Genomics has struck an agreement to use some of Rockefeller University’s viral and human microRNAs for therapeutic uses, the company said Wednesday.
 
Rosetta Genomics President and CEO Amir Avniel said the microRNAs offer the company access to more potential drug targets, and is in line with the its strategy to supplement its own research through licensing agreements with key academic centers. 
 
The company said it now has the rights to more than 500 microRNA targets.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.